We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

46 hedge funds and large institutions have $122M invested in MoonLake Immunotherapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

91.44% more ownership

Funds ownership: 0% → 91.44% (+91%)

Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
0.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.36M
3
BlackRock
BlackRock
New York
+$7.96M
4
RI
RTW Investments
New York
+$7.96M
5
RCM
RA Capital Management
Massachusetts
+$7.43M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$11.5M +$10.7M +1,011,589 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$8.53M +$8.36M +787,785 New
BlackRock
3
BlackRock
New York
$8.53M +$7.96M +750,153 New
RI
4
RTW Investments
New York
$8.53M +$7.96M +750,000 New
RCM
5
RA Capital Management
Massachusetts
$7.96M +$7.43M +700,000 New
Wellington Management Group
6
Wellington Management Group
Massachusetts
$7.58M +$7.43M +700,000 New
Citadel Advisors
7
Citadel Advisors
Florida
$7.44M +$7.29M +687,078 New
GTC
8
Ghost Tree Capital
New York
$5.68M +$5.31M +500,000 New
CAM
9
Cormorant Asset Management
Massachusetts
$4.74M +$4.57M +430,000 New
APM
10
Avidity Partners Management
Texas
$4.55M +$4.25M +400,000 New
BC
11
Boxer Capital
California
$4.55M +$4.25M +400,000 New
OCA
12
Octagon Capital Advisors
New York
$4.55M +$4.25M +400,000 New
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$3.64M +$3.4M +320,000 New
ACM
14
Altium Capital Management
New York
$2.84M +$2.65M +250,000 New
BCLSI
15
Bain Capital Life Sciences Investors
Massachusetts
$2.84M +$2.65M +250,000 New
FCMV
16
Foresite Capital Management V
California
$2.84M +$2.65M +250,000 New
TCM
17
Tekla Capital Management
Massachusetts
$2.71M +$2.65M +250,000 New
SCM
18
Silverarc Capital Management
Massachusetts
$2.44M +$2.28M +215,071 New
EC
19
EcoR1 Capital
California
$2.27M +$2.12M +200,000 New
LGM
20
Logos Global Management
California
$2.27M +$2.12M +200,000 New
SCM
21
Suvretta Capital Management
New York
$2.27M +$2.12M +200,000 New
RSCM
22
Rock Springs Capital Management
Maryland
$1.76M +$1.64M +154,500 New
6CM
23
683 Capital Management
New York
$1.71M +$1.59M +150,000 New
BCM
24
BlueCrest Capital Management
Jersey
$1.71M +$1.59M +150,000 New
CCM
25
Consonance Capital Management
New York
$1.69M +$1.59M +150,000 New
1
2

MLTX Hedge Fund Activity: Q4 2020 in Review

46 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2020, worth a combined $122M.

Buyers outnumbered sellers: 46 funds opened new MLTX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $10.7M.

  • 46 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $122M of MoonLake Immunotherapeutics stock for Q4 2020.
  • 46 funds opened new MoonLake Immunotherapeutics positions in Q4 2020 and 0 closed out, a net change of +46 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q4 2020 was Adage Capital Partners, an estimated $10.7M added.

Based on aggregated 13F filings for Q4 2020.